Eddingpharm Gains China Rights to Cancer Drug from Immutep

Eddingpharm has acquired China rights to Immutep’s ImmunFact IMP321, a treatment for breast cancer. Immutep is a French clinical-stage immuno-oncology biopharma. Eddingpharm will develop, commercialize and manufacture the drug, with rights extending to Hong Kong, Macau and Taiwan. Originally Eddingpharm and Immutep will develop the product as a first-line treatment for metastatic breast cancer and then pursue other metastatic indications. Financial details of the agreement were not disclosed. More details.... Share this with colleagues: // //